News

May 17, 2017May 17, 2017

New Patent Cover IL-23R Orally Stable Peptide Inhibitors Including Protagonist’s PTG-200 to Treat IBD

News

Protagonist Therapeutics has secured a patent covering orally stable peptide inhibitors of the interleukin-23 receptor (IL-23R), including its lead candidate drug PTG-200. The patent protects PTG-200’s formulation as well the use of this ... Read more

May 16, 2017

2 Molecules Identified with Potential Therapeutic Qualities for Chronic Inflammatory Conditions

News

Two molecules with anti-inflammatory qualities have been identified as potential new therapies for chronic conditions such as inflammatory bowel disease (IBD), researchers suggest. The study, “Cheminformatics-aided discovery of small-molecule Protein-Protein Interaction ... Read more

May 15, 2017May 15, 2017

Stress Management Could Help Treat Abdominal Pain in IBD Patients, British Study Suggests

News

Managing stress and changing the diets of patients with inflammatory bowel disease (IBD) may help mitigate abdominal pain, a British study suggests. The systematic review, “Interventions for abdominal pain management ... Read more

May 11, 2017

Zydus Wins Appeal in Shire’s Patent Case Over Generic Lialda for UC

News

Zydus Pharmaceuticals won a patent battle over Shire’s ulcerative colitis drug Lialda (mesalamine), with the U.S. Court of Appeals for the Federal Circuit ruling that Zydus’ proposed generic version of Lialda ... Read more

May 10, 2017

AbbVie’s Upadacitinib Benefits Crohn’s Patients in Phase 2 Trial, Supporting Advance to Phase 3

News

A Phase 2 trial (NCT02365649) of AbbVie’s investigational compound upadacitinib (ABT-494) showed the treatment had a positive effect in patients with Crohn’s disease, supporting the drug’s advance to Phase 3 ... Read more

May 9, 2017May 9, 2017

Entyvio Safe, Effective for Ulcerative Colitis and Crohn’s, Studies Show

News

Entyvio (vedolizumab) is safe and effective to treat adults with moderate-to-severe active ulcerative colitis (UC) and Crohn’s disease (CD). These results come from eight real-world analyses presented by Takeda Pharmaceutical ... Read more

May 8, 2017May 8, 2017

InDex to Present Positive Results of Kappaproct for Ulcerative Colitis at Digestive Disease Week Meeting

News

InDex Pharmaceuticals today presents positive results of its lead drug candidate Kappaproct (cobitolimod) to treat moderate to severe active ulcerative colitis (UC) during the Digestive Disease Week congress now underway in Chicago. The Swedish company ... Read more

May 5, 2017May 5, 2017

Most Crohn’s Fistulas Are Still Gone a Year After Cx601 Treatment, Trial Shows

News

TiGenix’s Cx601 was able to resolve a painful Crohn’s disease condition known as complex perianal fistulas for a year, according to a Phase 3 trial. Only a quarter of the patients ... Read more

May 4, 2017

Protagonist to Present Preclinical Findings on PTG-200 for Crohn’s Disease at Conference

News

Protagonist Therapeutics will present preclinical research data on its investigational drug PTG-200 as a potential treatment for Crohn’s disease. The findings will be presented May 6 at the Digestive Disease Week conference ... Read more

May 3, 2017May 3, 2017

Combining Curcumin with Essential Turmeric Oils Helps Fight Inflammation in Colitis, Baylor Study Finds

News

Essential turmeric oils (ETOs) can boost anti-inflammatory activity and significantly reduce colitis symptoms in experimental mouse models, finds a study suggesting that combined treatment of curcumin and ETOs is more powerful than ... Read more